Master Alliance Provisions Guide (MAPGuide)

CEPI CfP3i Template Funding Agreement

  • Equitable Access | Access plans & principles

<p class=”p1“><span style=”textdecoration: underline;”><strong>14. Equitable Access strong>span>p>
<p class=”p1“><i>[This Clause 14 is based on CEPIs expectation that most of the vaccines it helps to develop will not be profitmaking, particularly in low to middle income countries (“LMICs”) in affected areas where purchasing power is limited. It is CEPIs policy that access to these vaccines will be provided at a cost to LMICs that is fair both to the populations who need them and to CEPIs awardees who develop products.] i>p>
<p><strong>14.1 Equitable Access.strong> CEPI is committed to achieving equitable access to the outputs of all CEPIsupported programmes including access to all <a href=”#kt“>Project Resultsa>, pursuant to CEPIsEquitable AccessPolicy. Equitable Access to epidemic vaccines in the context of an <a href=”#kt“>Outbreaka> means that appropriate vaccines are first available to populations when and where they are needed to end an Outbreak or curtail an epidemic, regardless of ability to pay. CEPI is also committed to supporting Equitable Access so that the economics are sustainable to the manufacturer.p>
<p><strong>14.2 The Awardee will:strong> to the extent that Awardee commercializes Product which utilizes or otherwise benefits from, whether directly or indirectly, any Project Result, the distribution of that product in <a href=”#kt“>LMICsa> will be consistent with CEPIs <span style=”textdecoration: underline;”><a href=”https://cepi.net/wpcontent/uploads/2019/01/CEPIApproachtoEquitableAccess1312FINAL_0.pdftarget=”_blankrel=”noopener“>Equitable Access Policya>span> and <span style=”textdecoration: underline;”><a href=”https://cepi.net/wpcontent/uploads/2019/01/CEPICostGuidanceFINALv05.2020.pdftarget=”_blankrel=”noopener“>Cost Guidance Policya>,span> as well as with The Bill &amp; Melinda Gates Foundations approach to determining <span style=”textdecoration: underline;”><a href=”https://docs.gatesfoundation.org/Documents/Production_Economics_Vaccines_2016.pdftarget=”_blankrel=”noopener“>appropriate product costsa>span>.p>